Latest News

Later-Line CD19 and Bispecific Therapies Considered After CAR T
Later-Line CD19 and Bispecific Therapies Considered After CAR T

October 1st 2024

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.

From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma
From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma

September 18th 2024

Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL

September 16th 2024

Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma

September 11th 2024

Frontline Golcadomide/R-CHOP Shows Potent Antitumor Activity in Aggressive B-Cell Lymphoma
Frontline Golcadomide/R-CHOP Shows Potent Antitumor Activity in Aggressive B-Cell Lymphoma

September 10th 2024

More News